Arkolith/Insider Trading/PYXS/Form 4

Sullivan Lara

President and CEO, DirectorPyxis Oncology, Inc. (PYXS) · full profile →Form 4 · filed Mar 28, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
5
1 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 24, 2023Grant(A)703K—$02.2M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 24, 2023Disposed to issuer(D)990K——0
Mar 24, 2023Disposed to issuer(D)62K——0
Mar 24, 2023Grant(A)990K——990K
Mar 24, 2023Grant(A)62K——62K

Transaction Codes

A
Grant / award
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-021415) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for Pyxis Oncology, Inc.

Build

Build on these Form 4 transactions

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.

Form 4 insider API

Open-market buys and sells, cluster scans, company flows.

insider.transactions

13F holdings API

Owners, holdings, deltas, point-in-time portfolios.

stock.owners

MCP quickstart

Connect an agent, mint a key, make the first call.

/api/mcp